Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia/Ib BI 905711 plus chemotherapy in advanced gastrointestinal cancers
jRCT2031210462Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, randomised, open-label trial of BI 905711 in colorectal adenocarcinoma and pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum tolerated dose (MTD) of BI 905711 in Phase Ia, Number of patients with DLTs in Phase Ia and 2 more. Started Nov 2021; status: active, not recruiting.
02
Drugs
BI 905711
03
Conditions
colorectal adenocarcinomapancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2031210462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210462.